| Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing P Galanos, K Vougas, D Walter, A Polyzos, A Maya-Mendoza, ... Nature cell biology 18 (7), 777-789, 2016 | 278 | 2016 |
| The stress kinase p38α as a target for cancer therapy A Igea, AR Nebreda Cancer research 75 (19), 3997-4002, 2015 | 210 | 2015 |
| Dual function of p38α MAPK in colon cancer: suppression of colitis-associated tumor initiation but requirement for cancer cell survival J Gupta, I del Barco Barrantes, A Igea, S Sakellariou, IS Pateras, ... Cancer cell 25 (4), 484-500, 2014 | 188 | 2014 |
| Inhibition of p38 MAPK sensitizes tumour cells to cisplatin‐induced apoptosis mediated by reactive oxygen species and JNK L Pereira, A Igea, B Canovas, I Dolado, AR Nebreda EMBO molecular medicine 5 (11), 1759-1774, 2013 | 157 | 2013 |
| Meiosis requires a translational positive loop where CPEB1 ensues its replacement by CPEB4 A Igea, R Méndez The EMBO journal 29 (13), 2182-2193, 2010 | 121 | 2010 |
| Regulation of tumor angiogenesis and mesenchymal–endothelial transition by p38α through TGF-β and JNK signaling R Batlle, E Andrés, L Gonzalez, E Llonch, A Igea, N Gutierrez-Prat, ... Nature communications 10 (1), 3071, 2019 | 109 | 2019 |
| Lipid binding by the Unique and SH3 domains of c-Src suggests a new regulatory mechanism Y Pérez, M Maffei, A Igea, I Amata, M Gairí, AR Nebreda, P Bernadó, ... Scientific reports 3 (1), 1295, 2013 | 106 | 2013 |
| Targeting p38α increases DNA damage, chromosome instability, and the anti-tumoral response to taxanes in breast cancer cells B Cánovas, A Igea, AA Sartori, RR Gomis, TT Paull, M Isoda, ... Cancer cell 33 (6), 1094-1110. e8, 2018 | 90 | 2018 |
| Quantification of pathway cross-talk reveals novel synergistic drug combinations for breast cancer S Jaeger, A Igea, R Arroyo, V Alcalde, B Canovas, M Orozco, AR Nebreda, ... Cancer research 77 (2), 459-469, 2017 | 81 | 2017 |
| Resistance to taxanes in triple-negative breast cancer associates with the dynamics of a CD49f+ tumor-initiating population J Gómez-Miragaya, M Palafox, L Paré, G Yoldi, I Ferrer, S Vila, P Galván, ... Stem cell reports 8 (5), 1392-1407, 2017 | 78 | 2017 |
| Multi‐phosphorylation of the intrinsically disordered unique domain of c‐Src studied by in‐cell and real‐time NMR spectroscopy I Amata, M Maffei, A Igea, M Gay, M Vilaseca, AR Nebreda, M Pons ChemBioChem 14 (14), 1820-1827, 2013 | 68 | 2013 |
| Essential role of the Cdk2 activator RingoA in meiotic telomere tethering to the nuclear envelope P Mikolcevic, M Isoda, H Shibuya, I del Barco Barrantes, A Igea, JA Suja, ... Nature communications 7 (1), 11084, 2016 | 64 | 2016 |
| Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors J Gupta, A Igea, M Papaioannou, PP Lopez-Casas, E Llonch, M Hidalgo, ... Oncotarget 6 (11), 8539, 2015 | 43 | 2015 |
| A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia E Arriazu, C Vicente, R Pippa, I Peris, E Martínez-Balsalobre, ... Blood cancer journal 10 (1), 3, 2020 | 33 | 2020 |
| Global analysis of CPEBs reveals sequential and non-redundant functions in mitotic cell cycle V Giangarra, A Igea, CL Castellazzi, FA Bava, R Mendez PLoS One 10 (9), e0138794, 2015 | 32 | 2015 |
| Regulation of mammary luminal cell fate and tumorigenesis by p38α I del Barco Barrantes, CSO Attolini, K Slobodnyuk, A Igea, S Gregorio, ... Stem Cell Reports 10 (1), 257-271, 2018 | 20 | 2018 |
| MK2 degradation as a sensor of signal intensity that controls stress-induced cell fate N Gutierrez-Prat, M Cubillos-Rojas, B Cánovas, A Kuzmanic, J Gupta, ... Proceedings of the National Academy of Sciences 118 (29), e2024562118, 2021 | 15 | 2021 |
| Central Role of Semaphorin 3B in a Serum‐Induced Arthritis Model and Reduced Levels in Patients With Rheumatoid Arthritis A Igea, T Carvalheiro, B Malvar‐Fernández, S Martinez‐Ramos, ... Arthritis & Rheumatology 74 (6), 972-983, 2022 | 14 | 2022 |
| Changes in the immune phenotype and gene expression profile driven by a novel tuberculosis nanovaccine: short and long-term post-immunization A Martínez-Pérez, A Igea, O Estévez, CM Ferreira, E Torrado, AG Castro, ... Frontiers in Immunology 11, 589863, 2021 | 9 | 2021 |
| Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses N Silva-Pilipich, E Blanco, T Lozano, E Martisova, A Igea, ... Cancer Letters 561, 216139, 2023 | 5 | 2023 |
